Chemotherapy plus immunotherapy before surgery for bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy, an immunotherapy drug called adebrelimab, and a supportive medication to shrink bile duct or gallbladder tumors before surgery. The goal is to make the tumor easier to remove and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of bile duct or gallbladder cancer that is locally advanced (has not spread far) and is hard to remove with surgery right away.
- You must not have received prior treatment (like chemo or radiation) for this cancer.
- You must be generally healthy and able to care for yourself (ECOG score 0 or 1).
- You must not have an autoimmune disease or a serious allergy to certain antibodies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug given before surgery for bile duct cancer. The goal is to see if this approach shrinks tumors and lowers the chance of cancer coming back after surgery.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests a combination of drugs given before surgery to shrink bile duct cancer and possibly improve outcomes. The drugs include an immunotherapy (tislelizumab) and three chemotherapy agents (gemcitabine, cisplatin, and S-1).
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.